How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analysts' expectations of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%. Read the conference call transcript .

When did Nabriva Therapeutics' stock split?

Nabriva Therapeutics's stock reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Agile Therapeutics (AGRX) , Dynavax Technologies (DVAX) , Acasti Pharma (ACST) , Amarin (AMRN) , AcelRx Pharmaceuticals (ACRX) , Sorrento Therapeutics (SRNE) , Vaxart (VXRT) and Heat Biologics (HTBX) .

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free NBRV Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.00
▼
$0.52
52-Week Range: N/A

Volume: N/A
Average Volume: 29,344 shs
Market Capitalization: $45.46 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Earnings Financials Insider Trades SEC Filings Social Media

Get Nabriva Therapeutics alerts:

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

NBRV Stock News Headlines

April 13, 2024 | morningstar.com

Nabriva Therapeutics PLC NBRVF

April 9, 2024 | americanbankingnews.com

Nabriva Therapeutics (NASDAQ:NBRV) Receives New Coverage from Analysts at StockNews.com

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

July 11, 2023 | finanznachrichten.de

Arbutus Biopharma Corporation: Arbutus Appoints Two New Executives

May 26, 2023 | finance.yahoo.com

NBRV - Nabriva Therapeutics plc

February 28, 2023 | marketwatch.com

Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029

February 25, 2023 | seekingalpha.com

NBRV Nabriva Therapeutics plc

January 6, 2023 | finance.yahoo.com

Nabriva Therapeutics Provides Corporate Update

April 16, 2024 | InvestorPlace (Ad)

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

November 28, 2022 | marketwatch.com

Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data

November 28, 2022 | markets.businessinsider.com

Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis

November 28, 2022 | markets.businessinsider.com

Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up

November 28, 2022 | bizjournals.com

Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | seekingalpha.com

Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate

November 28, 2022 | finance.yahoo.com

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

November 28, 2022 | finance.yahoo.com

Nabriva's stock is up after sharing antibiotic news

November 28, 2022 | finance.yahoo.com

Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment

November 10, 2022 | finance.yahoo.com

Montgomery County biopharmaceutical firm reducing workforce by 40%

November 10, 2022 | technews.tmcnet.com

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

November 10, 2022 | finance.yahoo.com

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

November 7, 2022 | finance.yahoo.com

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

September 15, 2022 | finance.yahoo.com

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

September 14, 2022 | finance.yahoo.com

All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy

September 6, 2022 | finance.yahoo.com

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 12, 2022 | marketwatch.com

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis

August 11, 2022 | finance.yahoo.com

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

August 4, 2022 | seekingalpha.com

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call Transcript

See More Headlines

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/06/2021
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NBRV
CUSIP: N/A
CIK: 1641640
Web: www.nabriva.com
Phone: (531) 649-2000
Fax: 610-816-6639
Employees: 39
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($19.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,190,000.00
Net Margins: -148.11%
Pretax Margin: -144.78%
Return on Equity: -365.53%
Return on Assets: -135.81%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 0.85
Quick Ratio: 0.52

Sales & Book Value

Annual Sales: $35.59 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 32,015,000
Free Float: 31,493,000
Market Cap: $45.46 million
Optionable: Not Optionable
Beta: 1.53

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Colin Broom M.D. (Age 67)
Director
Comp: $40k
Mr. J. Christopher Naftzger BA (Age 56)
Esq., J.D., Interim CEO, Gen. Counsel & Sec.
Mr. Daniel Dolan (Age 46)
Chief Financial Officer

Key Competitors

View All Competitors

NBRV Stock Analysis - Frequently Asked Questions

How were Nabriva Therapeutics' earnings last quarter?: Nabriva Therapeutics plc (NASDAQ:NBRV) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analysts' expectations of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%.
Read the conference call transcript.
When did Nabriva Therapeutics' stock split?: Nabriva Therapeutics's stock reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Nabriva Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).
How do I buy shares of Nabriva Therapeutics?: Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBRV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

NBRV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NBRV Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info